Founder & CEO
San Francisco, CA
Savan is the Founder and CEO of BioTrillion, a health technology company developing BioEngine4D to digitally detect developing diseases. Previously, Savan spent the majority of his 15 year career in the Life Sciences industry working with hundreds of public and private corporations as a Healthcare Investment Banker at Citigroup, Deutsche Bank. From Analyst through Managing Director, he led ~40 financing, IPO, and M&A deals, totaling $35+ billion in deal value, and experienced many invaluable business and scientific lessons from his work with clients across the spectrum of drug, diagnostic, and device technologies such as Amgen, Anacor, Boston Scientific, Eli Lilly, Intermune, Map Pharma, Masimo, Medtronic, Omeros, Pacific Biosciences, and many others. While a Vice President at Deutsche Bank, Savan was selected to lead the firm's Healthcare business expansion into Asia, leading to IPO's of the two largest healthcare companies in China, Shanghai Pharma and Fosun Pharma. Savan began his career as a Bioengineer at Life Technologies. Savan graduated with a M.S.E. in Bioengineering from the University of Pennsylvania, with an emphasis in Business from Wharton and a B.S.E. in Bioengineering focused in Computer Science from the University of California at Berkeley. After many years of academic and professional experience in the healthcare field, a deeply personal experience later in life gave Savan a new perspective into how much healthcare needed to change – his mother was abruptly diagnosed with stage IVb cancer. This compelled Savan to ask “where were all the signs” and “isn't there a better way,” which led to BioTrillion.
BioTrillion is a startup developing a health technology platform called BioEngine4D to digitally detect developing diseases by aggregating smart device sensor-generated phenotypic LIFEdata, analyzing it through computational advancements in machine learning and artificial intelligence, and applying it back to life. Our core mission is to optimize human quality of life and longevity by detecting diseases earlier in the health-continuum. We believe that Data from Life should be Data for Life. Our solution is largely predicated on the novelty, complexity, and accuracy of BioEngine4D. Moreover, BioEngine4D becomes maximally commercializable with a front-end mobile App layer that is versatile for both consumers and health professionals, intuitive to use, and value-additive to adopt. BioTrillion provides users of its platform with valuable health analytics, engagement features, and statistically significant insights into the development of key diseases, catalyzing action and earlier clinical-confirmatory diagnoses and intervention. The world is currently at the nexus of multiple tailwinds occurring technologically and behaviorally. Recently disruptive technologies and advancing clinical behaviors have enabled BioTrillion’s mission to be realizable. We believe it is crucial to understand both the synergies and the boundaries where the domains of Biology + Technology intersect and have been assembling a team with a rare combination of life, data, and computer sciences backgrounds, across business and engineering. BioTrillion believes the next phase in Consumer Healthcare will transcend from “Wellness” to “Detection.”